Table 2.
Association analysis of SNPs/haplotypes with OS in NSCLC patients treated with gemcitabine
| (A). The top 5 SNPs associated with patient OS.
| ||||||||
|---|---|---|---|---|---|---|---|---|
| SNP | P_value | HR (95% CI) | Gene | Chromosome | Position | MAF_Caucasion | Location | Allele |
| rs2274341 | 0.011 | 1.256 (1.053 – 1.499) | NT5C2 | 10 | 105000000 | 0.229 | Intron | C/T |
| rs9394992 | 0.012 | 0.792 (0.660 – 0.950) | SLC29A1 | 6 | 44302323 | 0.317 | Intron | A/G |
| rs720106 | 0.016 | 1.899 (1.124 – 3.206) | RRM1 | 11 | 4096554 | 0.017 | Intron | A/G |
| rs747199 | 0.027 | 0.782 (0.630 – 0.972) | SLC29A1 | 6 | 44302323 | 0.192 | Intron | A/G |
| rs818194 | 0.039 | 1.209 (1.009 – 1.448) | CDA | 1 | 20804415 | 0.208 | Intron | C/T |
| (B). Haplotype analysis for OS in NSCLC patients.
| |||||
|---|---|---|---|---|---|
| Gene | Hap code | P_value | HR (95% CI) | Haplotype | Hap Freq |
| RRM1 | mhap.2 | 0.007 | 0.316 (0.137 – 0.730) | ACGA | 0.017 |
| mhap.4 | 0.008 | 0.458 (0.257 – 0.815) | CCAA | 0.097 | |
| mhap.5 | 0.033 | 0.565 (0.334 – 0.955) | CCGA | 0.590 | |
| mhap.1 | 0.046 | 0.574 (0.332 – 0.991) | ACAA | 0.242 | |
|
| |||||
| RRM2 | mhap.3 | 0.009 | 1.308 (1.070 – 1.599) | CA | 0.201 |
|
| |||||
| SLC28A3 | mhap.66 | 0.001 | 4.648 (1.890 – 11.433) | GAGCAGAAAGGGAACCGGAGACATTAAGA | 0.008 |
| mhap.143 | 0.022 | 0.523 (0.301 – 0.912) | GCACGAGCAAGGGACCGGAGACAATAAGA | 0.028 | |
| mhap.116 | 0.037 | 0.681 (0.474 – 0.977) | GAGCAGGCGGGGGGGCGGAGACATTAAGA | 0.087 | |
|
| |||||
| SLC29A1 | mhap.15 | 0.028 | 0.019 (0.001 – 0.649) | CGAGA | 0.007 |
HR, hazard ratio; HR > 1 indicates that subjects carrying the minor allele had a worse OS. The 95% confidence interval (CI) for the HR is listed with the P-value.